Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19
Condition: Coronavirus Infections Interventions: Drug: tixagevimab/cilgavimab 150+150 mg; Drug: tixagevimab/cilgavimab 300+300 mg; Drug: regdanvimab Sponsors: City Clinical Hospital No.52 of Moscow Healthcare Department; Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials